GeneDx announced it is acquiring Fabric Genomics, a pioneer in AI-powered genomic interpretation. The deal aims to support “GeneDx’s leadership in the next phase of genomic medicine: decentralized testing with centralized intelligence,” according to the press release. The deal is worth potentially just over $50M.
“Healthcare is at an inflection point where integrating genomic insights into standard care is becoming essential—both for better clinical outcomes and for saving the healthcare system valuable dollars. To achieve this, we must evolve and provide adaptable solutions so this information can be used more proactively and without geographic constraints,” said Katherine Stueland, president and CEO of GeneDx.
She added, “Adding Fabric Genomics and their talented team moves us closer to that future, enabling our partners to deliver groundbreaking genomic insights to patients across the globe.”
The deal will give clients access to GeneDx’s centralized lab or let them perform sequencing at their institutions and then have access to Fabric Genomics’ AI-powered interpretation platform. The aim is to accelerate faster and earlier diagnosis of genetic diseases, delivering improved outcomes for patients, and reducing unnecessary costs for healthcare systems in the United States and globally.
“This marks an exciting new chapter for Fabric Genomics. By joining forces with GeneDx, we’re combining two of the most powerful engines in genomic medicine, our AI-driven interpretation platform and GeneDx’s unparalleled rare disease data set,” said Martin Reese, PhD, co-founder, president, and CEO, Fabric Genomics. “Together, we’ll make genome interpretation faster, more scalable, and more impactful, enabling clinicians to deliver precise answers and care to patients worldwide. This combination accelerates our founding mission to end the diagnostic odyssey and bring the full promise of genomic medicine into everyday healthcare and expedite the delivery of life-changing treatments.”
The acquisition will expand GeneDx’s market in key areas, including:
NICU testing: Each year, over 400,000 infants are admitted to U.S. NICUs, yet fewer than 5% of infants in the NICU receive a genetic test. Studies show rapid whole genome sequencing reduces diagnostic time and cost while improving outcomes.
Genomic newborn screening: With 3.7 million births annually in the United States and over 130 million globally, the newborn genomic screening market represents one of the largest long-term opportunities in diagnostics. GeneDx is already a leader in this field and part of the GUARDIAN study.
Global commercial expansion: As global health systems shift toward data sovereignty and local sequencing, Fabric Genomics’ cloud-native platform should help GeneDx deliver centralized AI interpretation while complying with local regulations. This cloud-native architecture supports flexible go-to-market strategies—enterprise software-as-a-service (SaaS), usage-based interpretation-as-a-service (IaaS), or embedded interpretation in national lab networks—and expands GeneDx’s ability to serve regions such as EMEA, APAC, Canada, LATAM, and emerging markets with tailored commercial models.
Scaling precision genomics: With more than 750,000 exomes/genomes sequenced, GeneDx has a significant footprint in precision genomics. Fabric Genomics brings software that, among other things, adds high-leverage interpretation services.
“Both teams are united by a shared vision for the future of healthcare, a world where every genetic disorder is diagnosed as early as possible, paving the way for faster, more effective treatment and giving patients the greatest chance at living long, healthy lives,” said Stueland.
GeneDx will pay up to an aggregate of $33 million in cash, with total consideration potentially up to an aggregate of $51 million upon achievement of certain milestones. At closing, Fabric will continue to operate independently, maintaining its momentum and fostering organic growth. However, GeneDx will provide commercial support both in the United States and internationally.
